Verrica Pharmaceuticals Inc. (VRCA)
| Market Cap | 228.96M |
| Revenue (ttm) | 12.00M |
| Net Income (ttm) | -38.52M |
| Shares Out | 27.52M |
| EPS (ttm) | -1.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 37,882 |
| Open | 8.29 |
| Previous Close | 8.29 |
| Day's Range | 8.25 - 8.70 |
| 52-Week Range | 8.16 - 18.42 |
| Beta | 2.04 |
| Analysts | Buy |
| Price Target | 19.50 (+134.4%) |
| Earnings Date | Nov 15, 2021 |
About VRCA
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; which has completed phase II clinical trial for treating common warts; and that is in phase II clinical trial for the treatment of external genital warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agr...
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for VRCA stock is "Buy." The 12-month stock price forecast is 19.50, which is an increase of 134.38% from the latest price.
News
FDA Accepts Verrica's Resubmission For VP-102 For Contagious Skin Disease
The FDA has accepted Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) resubmitted marketing application seeking approval for VP-102 to treat molluscum contagiosum (molluscum), a common, highly contagious sk...
Verrica Pharmaceuticals Announces Acceptance by FDA of NDA Resubmission for VP-102 for the Treatment of Molluscum Con...
WEST CHESTER, Pa., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medica...
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Cont...
WEST CHESTER, Pa., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medica...
Verrica Pharmaceuticals Announces FDA Acceptance of its IND Application for LTX-315, a Potential First-in-Class Oncol...
Company expects to initiate Phase 2 trial in basal cell carcinoma in 1Q 2022
Verrica Pharmaceuticals Reports Third Quarter 2021 Financial Results
Contract Manufacturer identified in prior CRL receives satisfactory resolution (VAI) of the facility's identified deficiencies from the FDA
Does Verrica Pharmaceuticals Inc. (VRCA) Have the Potential to Rally 60% as Wall Street Analysts Expect?
The mean of analysts' price targets for Verrica Pharmaceuticals Inc. (VRCA) points to a 59.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agree...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Verrica Pharmaceuticals Inc. -VRCA
NEW YORK, Sept. 23, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: VRCA).
Why Verrica Pharmaceuticals Stock Is Getting Pummeled Today
The Food and Drug Administration delivered some bad news regarding the company's dermatology candidate.
Why Verrica Pharmaceuticals Shares Are Trading Lower Today
Verrica Pharmaceuticals (NASDAQ:VRCA) shares are trading lower after the company announced the FDA issued a Complete Response Letter regarding its New Drug Application for VP-102 for the treatment of mo...
Verrica (VRCA) Gets CRL From the FDA for Skin Disease Drug
Verrica (VRCA) suffers a setback yet again as the FDA issues a CRL for its lead product candidate VP-102. Consequently, shares are trading down.
Verrica Pharma Shares Slide After Response Letter From FDA
The FDA has issued a Complete Response Letter (CRL) regarding Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) marketing application seeking approval for VP-102 for molluscum contagiosum, a highly contagiou...
Verrica Pharmaceuticals Receives Complete Response Letter from the FDA identifying deficiencies at a facility of a Co...
No Specific Deficiencies Related to the Manufacturing of VP-102 Identified by FDA in its General Inspection of a Facility of the Contract Manufacturer
Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results
WEST CHESTER, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medica...
Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer
Company strengthens management team in anticipation of the potential commercial launch of VP-102, if approved
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verrica Pharmaceuticals Inc. - VRCA
New York, New York--(Newsfile Corp. - June 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: VRCA). Such inves...
Verrica's (VRCA) Skin Disease Candidate Approval Gets Delayed
Verrica's (VRCA) NDA for lead candidate, VP-102, a drug-device combination treatment for skin disease, molluscum, is under review. FDA delays decision on potential approval for the candidate by three mo...
Verrica's VP-102 Application Review for Molluscum Contagiosum Delayed till September
The FDA has extended the review period for the marketing application for Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) VP-102 to treat molluscum contagiosum (molluscum). Now the Prescription Drug User Fe...
Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum...
– Prescription Drug User Fee Act (PDUFA) goal date extended by three months to September 23, 2021 –
Verrica Pharmaceuticals Announces Participation in the Jefferies Virtual Healthcare Conference
WEST CHESTER, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical...
Verrica Pharmaceuticals Announces Participation in the 2021 RBC Capital Markets Global Healthcare Conference
WEST CHESTER, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical...
Verrica Pharmaceuticals Reports First Quarter 2021 Financial Results
– Expanded commercial team in preparation for potential FDA approval of VP-102 for the treatment of molluscum, which has been assigned a PDUFA goal date of June 23, 2021 –
Verrica Pharmaceuticals Announces Participation in the 20th Annual Needham Virtual Healthcare Conference
WEST CHESTER, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medic...
Verrica Announces Election of Gary Goldenberg, MD, Verrica's Chief Medical Officer, to Membership in the American Der...
WEST CHESTER, Pa., March 29, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical...
Verrica Announces Pricing of Public Offering of Common Stock
WEST CHESTER, Pa., March 22, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical...
Verrica Announces Proposed Public Offering of Common Stock
WEST CHESTER, Pa., March 22, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical intervent...